erythromycin B : An erythromycin that consists of erythronolide B having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 9918244 |
| CHEMBL ID | 3220708 |
| CHEBI ID | 28196 |
| SCHEMBL ID | 193989 |
| MeSH ID | M0178094 |
| Synonym |
|---|
| an686jj1yi , |
| abbott-24091 |
| unii-an686jj1yi |
| 527-75-3 |
| D03098 |
| berythromycin (usan/inn) |
| abbot 24091 |
| beritromicina [inn-spanish] |
| erythromycin, 12-deoxy- |
| berythromycinum [inn-latin] |
| berythromycin [usan:inn] |
| brn 5206722 |
| berythromycine [inn-french] |
| erythromycin b |
| berythromycin |
| C06653 |
| beritromicina |
| berythromycine |
| 12-deoxyerythromycin |
| CHEBI:28196 , |
| berythromycinum |
| (3r,4s,5s,6r,7r,9r,11r,12s,13r,14r)-4-(2,6-dideoxy-3-c-methyl-3-o-methyl-alpha-l-ribo-hexopyranosyloxy)-14-ethyl-7,12-dihydroxy-6-[3,4,6-trideoxy-3-(dimethylamino)-beta-d-xylo-hexopyranosyloxy]-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione |
| LMPK04000012 |
| erythromycin-b |
| bdbm85998 |
| ERB , |
| berythromycin [usan] |
| erythromycin b [usp-rs] |
| erythromycin, 12-deoxy |
| berythromycin [who-dd] |
| berythromycin [inn] |
| CHEMBL3220708 |
| SCHEMBL193989 |
| (3r,4s,5s,6r,7r,9r,11r,12s,13r,14r)-6-{[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2h-pyran-2-yl]oxy}-14-ethyl-7,12-dihydroxy-4-{[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2h-pyran-2-yl]oxy}-3,5,7,9,11,13-hexamethyloxacycl |
| IDRYSCOQVVUBIJ-PPGFLMPOSA-N |
| Q27103559 |
| (3r,4s,5s,6r,7r,9r,11r,12s,13r,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12-dihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione |
| erythromycin b (150 mg) |
| DTXSID501023765 |
| Class | Description |
|---|---|
| erythromycin | Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus). |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (18.18) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||